blisibimod

Home
Ligands
blisibimod

GtoPdb Ligand ID: 9518

Synonyms: A-623 | AGP3 peptibody [5] | AMG 623 | Fc-Agp-3 [1]

Compound class: Peptide or derivative

Comment: Blisibimod is a peptibody fusion containing four BAFF binding domains fused to a human Fc domain. By sequestering circulating BAFF ligand, it acts as a functional antagonist of BAFF interaction with the TACI receptor on B cells.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for blisibimod is claimed in Amgen's patent WO2002092620 [5].

References
1. Callahan WJ, Remmele RL Jr, Ratnaswamy G, Latypov RF, Liu D. (2016) Lyophilized therapeutic peptibody formulations. Patent number: US9283260. Assignee: Amgen Inc.. Priority date: 21/04/2006. Publication date: 15/03/2016.
2. Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA, PEARL-SC Study. (2015) A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis, 74 (9): 1667-75. [PMID:24748629]
3. Lazaro E, Scherlinger M, Truchetet ME, Chiche L, Schaeverbeke T, Blanco P, Richez C. (2017) Biotherapies in systemic lupus erythematosus: New targets. Joint Bone Spine, 84 (3): 267-274. [PMID:27663753]
4. Lenert A, Niewold TB, Lenert P. (2017) Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. Drug Des Devel Ther, 11: 747-757. [PMID:28331294]
5. Min H, Hsu H, Xiong F. (2002) Peptides and related molecules that bind to tall-1. Patent number: WO2002092620. Assignee: Amgen, Inc.. Priority date: 11/05/2001. Publication date: 21/11/2002.
6. Scheinberg MA, Hislop CM, Martin RS. (2016) Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. Expert Opin Biol Ther, 16 (5): 723-33. [PMID:27051973]
7. Stohl W. (2014) Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets, 18 (4): 473-89. [PMID:24521424]

References

1. Callahan WJ, Remmele RL Jr, Ratnaswamy G, Latypov RF, Liu D. (2016)
Lyophilized therapeutic peptibody formulations.
Patent number: US9283260. Assignee: Amgen Inc.. Priority date: 21/04/2006. Publication date: 15/03/2016.

2. Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA, PEARL-SC Study. (2015)
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Ann Rheum Dis, 74 (9): 1667-75. [PMID:24748629]

3. Lazaro E, Scherlinger M, Truchetet ME, Chiche L, Schaeverbeke T, Blanco P, Richez C. (2017)
Biotherapies in systemic lupus erythematosus: New targets.
Joint Bone Spine, 84 (3): 267-274. [PMID:27663753]

4. Lenert A, Niewold TB, Lenert P. (2017)
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.
Drug Des Devel Ther, 11: 747-757. [PMID:28331294]

5. Min H, Hsu H, Xiong F. (2002)
Peptides and related molecules that bind to tall-1.
Patent number: WO2002092620. Assignee: Amgen, Inc.. Priority date: 11/05/2001. Publication date: 21/11/2002.

6. Scheinberg MA, Hislop CM, Martin RS. (2016)
Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.
Expert Opin Biol Ther, 16 (5): 723-33. [PMID:27051973]

7. Stohl W. (2014)
Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
Expert Opin Ther Targets, 18 (4): 473-89. [PMID:24521424]